Ding Dong is the Skinny Label (Effectively) Dead?
FDA Law Blog
SEPTEMBER 6, 2021
Teva case, that the statutory provisions governing patent infringement, specifically induced infringement, do not address carve-outs. Teva received tentative approval in June 2003 and launched in 2007 after a blocking patent expired. Instead, it was GSK who erred in omitting the post-MI language from the use code.
Let's personalize your content